EUVIMEDEUVIMED entdecken
Crossref

Development of a Composite Score Based on Carbohydrate Antigen 19-9 Dynamics to Predict Survival in Carbohydrate Antigen 19-9–Producing Patients With Pancreatic Ductal Adenocarcinoma After Neoadjuvant Treatment

Ingmar F Rompen iD, Elisabetta Sereni, Joseph R Habib iD, Jonathan Garnier iD, Veronica Galimberti iD, Lucas R Perez Rivera iD, Deepa Vatti iD, Kelly J Lafaro iD, D Brock Hewitt, Greg D Sacks iD, William R Burns, Steven Cohen und 6 weitere

JCO Precision Oncology · 2024

DOI: 10.1200/po.24.00193 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2024. Verfasst von Ingmar F Rompen und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, The NYU Grossman School of Medicine and NYU Langone Health, New York, NY. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Neoadjuvant Therapy, Pancreatic Neoplasms, CA-19-9 Antigen. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Dynamics of carbohydrate antigen 19-9 (CA19-9) often inform treatment decisions during and after neoadjuvant chemotherapy (NAT) of patients with pancreatic ductal adenocarcinoma (PDAC). However, considerable dispute persists regarding the clinical relevance of specific CA19-9 thresholds and dynamics. Therefore, we aimed to define optimal thresholds for CA19-9 values and create a biochemically driven composite score to predict survival in CA19-9-producing patients with PDAC after NAT. METHODS Patients with PDAC who underwent NAT and surgical resection from 2012 to 2022 were retrospectively identified from three high-volume centers. CA19-9 nonproducers and patients with 90-day mortality, and macroscopically incomplete resections were excluded. A composite score was created on the basis of relative CA19-9 change and newly defined optimal thresholds of pre- and postneoadjuvant values for overall survival (OS) using patients from two centers and validated using data from the third center. RESULTS A total of 492 patients met inclusion criteria in the development cohort. Optimal CA19-9 cutoff values for predicting a difference in OS were 202 U/mL for preneoadjuvant and 78 U/mL for postneoadjuvant levels. Furthermore, increase in CA19-9 during neoadjuvant treatment was associated with worse OS (median-OS, 17.5 months v 26.0 months; P = .008). Not surpassing any or only one of these thresholds (composite score of 0-1) was associated with improved OS compared with patients with 2-3 points (median-OS, 29.9 months v 15.8 months; P < .001). Major serological response (90% decrease of CA19-9) had a positive and negative predictive value of 32% and 88%, respectively. CONCLUSION The composite score consisting of CA19-9 levels at diagnosis, after neoadjuvant treatment, and its dynamics demonstrates prognostic discrimination between low and high scores. However, better predictive biomarkers are needed to facilitate treatment decisions during neoadjuvant treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Pancreatic DuctalNeoadjuvant TherapyPancreatic NeoplasmsCA-19-9 AntigenHumansMaleFemaleMiddle AgedAgedRetrospective StudiesAdultPrognosis

Substanzen

CA-19-9 Antigen

Autor:innen und Institutionen

  • Department of Surgery, The NYU Grossman School of Medicine and NYU Langone Health, New York, NY.
  • Department of General, Visceral, and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, Germany.
  • Department of General and Pancreatic Surgery, The Pancreas Institute, University of Verona Hospital Trust, Verona, Italy.
  • Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD.
  • Department of Surgical Oncology, Aix-Marseille University, CRCM, Institut Paoli-Calmettes, Marseille, France.

ORCID-Profile: Ingmar F Rompen, Joseph R Habib, Jonathan Garnier, Veronica Galimberti, Lucas R Perez Rivera, Deepa Vatti, Kelly J Lafaro, Greg D Sacks, Jin He, Ammar A Javed

Zitieren

APA

Rompen, I. F., Sereni, E., Habib, J. R., Garnier, J., Galimberti, V., Perez Rivera, L. R., Vatti, D., Lafaro, K. J., Hewitt, D. B., Sacks, G. D., Burns, W. R., Cohen, S., Kaplan, B., Burkhart, R. A., Turrini, O., Wolfgang, C. L., He, J., & Javed, A. A. (2024). Development of a Composite Score Based on Carbohydrate Antigen 19-9 Dynamics to Predict Survival in Carbohydrate Antigen 19-9–Producing Patients With Pancreatic Ductal Adenocarcinoma After Neoadjuvant Treatment. JCO Precision Oncology. https://doi.org/10.1200/po.24.00193

Vancouver

Rompen IF, Sereni E, Habib JR, Garnier J, Galimberti V, Perez Rivera LR, et al. Development of a Composite Score Based on Carbohydrate Antigen 19-9 Dynamics to Predict Survival in Carbohydrate Antigen 19-9–Producing Patients With Pancreatic Ductal Adenocarcinoma After Neoadjuvant Treatment. JCO Precision Oncology. 2024. doi:10.1200/po.24.00193

BibTeX
@article{Rompen2024,
  author = {Rompen, Ingmar F and Sereni, Elisabetta and Habib, Joseph R and Garnier, Jonathan and Galimberti, Veronica and Perez Rivera, Lucas R and Vatti, Deepa and Lafaro, Kelly J and Hewitt, D Brock and Sacks, Greg D and Burns, William R and Cohen, Steven and Kaplan, Brian and Burkhart, Richard A and Turrini, Olivier and Wolfgang, Christopher L and He, Jin and Javed, Ammar A},
  title = {Development of a Composite Score Based on Carbohydrate Antigen 19-9 Dynamics to Predict Survival in Carbohydrate Antigen 19-9–Producing Patients With Pancreatic Ductal Adenocarcinoma After Neoadjuvant Treatment},
  journal = {JCO Precision Oncology},
  year = {2024},
  doi = {10.1200/po.24.00193}
}
Kostenlos starten →